Nanotech Boom Presents Challenges For Both Industry, Regulators
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is ready to protect public from unsafe nano-materials despite challenges of regulating nanotech development, the agency says at Baltimore roundtable.
You may also be interested in...
FDA Ramps Up Data Gathering On How To Regulate Nanotech In Drugs, Biologics
By 2015, some predict, nanotechnology will play a critical role in up to 60% of biopharma products.
FDA Ramps Up Data Gathering On How To Regulate Nanotech In Drugs, Biologics
By 2015, some predict, nanotechnology will play a critical role in up to 60% of biopharma products.
Nanotechnology, Bioequivalence On Pharmaceutical Science Panel Agenda
Need for guidance on orally disintegrating tablets as a separate dosage form also on July 22-23 agenda.